company background image
DEST

Destiny PharmaAIM:DEST Stock Report

Market Cap

UK£66.7m

7D

-2.2%

1Y

52.7%

Updated

16 Oct, 2021

Data

Company Financials +
DEST fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

DEST Overview

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom.

Price History & Performance

Summary of all time highs, changes and price drops for Destiny Pharma
Historical stock prices
Current Share PriceUK£1.12
52 Week HighUK£0.60
52 Week LowUK£2.50
Beta0.24
1 Month Change-5.11%
3 Month Change-9.72%
1 Year Change52.74%
3 Year Change42.95%
5 Year Changen/a
Change since IPO-48.74%

Recent News & Updates

Aug 05
Will Destiny Pharma (LON:DEST) Spend Its Cash Wisely?

Will Destiny Pharma (LON:DEST) Spend Its Cash Wisely?

There's no doubt that money can be made by owning shares of unprofitable businesses. Indeed, Destiny Pharma ( LON:DEST...

Apr 16
Is Destiny Pharma (LON:DEST) In A Good Position To Invest In Growth?

Is Destiny Pharma (LON:DEST) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Shareholder Returns

DESTGB BiotechsGB Market
7D-2.2%2.8%1.7%
1Y52.7%23.6%22.9%

Return vs Industry: DEST exceeded the UK Biotechs industry which returned 23.6% over the past year.

Return vs Market: DEST exceeded the UK Market which returned 22.9% over the past year.

Price Volatility

Is DEST's price volatile compared to industry and market?
DEST volatility
DEST Beta0.24
Industry Beta0.83
Market Beta1

Stable Share Price: DEST is not significantly more volatile than the rest of UK stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: DEST's weekly volatility has decreased from 10% to 5% over the past year.

About the Company

FoundedEmployeesCEOWebsite
199614Neil Clarkhttps://www.destinypharma.com

Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of medicines for the treatment of infectious diseases in the United Kingdom. The company is involved in developing NTCD-M3 that is in phase III clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal that is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal, which is in Phase I clinical trial for the treatment of skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Biofilm for the treatment of of antibiotic resistant biofilm and bacterial aggregate associated infections.

Destiny Pharma Fundamentals Summary

How do Destiny Pharma's earnings and revenue compare to its market cap?
DEST fundamental statistics
Market CapUK£66.75m
Earnings (TTM)-UK£5.47m
Revenue (TTM)UK£12.45k

5.6kx

P/S Ratio

-12.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
DEST income statement (TTM)
RevenueUK£12.45k
Cost of RevenueUK£0
Gross ProfitUK£12.45k
ExpensesUK£5.48m
Earnings-UK£5.47m

Last Reported Earnings

Jun 30, 2021

Next Earnings Date

n/a

Earnings per share (EPS)-0.091
Gross Margin100.00%
Net Profit Margin-43,931.60%
Debt/Equity Ratio0.0%

How did DEST perform over the long term?

See historical performance and comparison

Valuation

Is Destiny Pharma undervalued compared to its fair value and its price relative to the market?

6.57x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate DEST's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate DEST's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: DEST is unprofitable, so we can't compare its PE Ratio to the UK Biotechs industry average.

PE vs Market: DEST is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate DEST's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: DEST is overvalued based on its PB Ratio (6.6x) compared to the GB Biotechs industry average (6.3x).


Future Growth

How is Destiny Pharma forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

14.8%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Destiny Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Destiny Pharma performed over the past 5 years?

-21.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: DEST is currently unprofitable.

Growing Profit Margin: DEST is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: DEST is unprofitable, and losses have increased over the past 5 years at a rate of 21.8% per year.

Accelerating Growth: Unable to compare DEST's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: DEST is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.6%).


Return on Equity

High ROE: DEST has a negative Return on Equity (-53.81%), as it is currently unprofitable.


Financial Health

How is Destiny Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: DEST's short term assets (£8.2M) exceed its short term liabilities (£349.4K).

Long Term Liabilities: DEST has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: DEST is debt free.

Reducing Debt: DEST has not had any debt for past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: DEST has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: DEST has sufficient cash runway for 1.1 years if free cash flow continues to reduce at historical rates of 34.4% each year.


Dividend

What is Destiny Pharma current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate DEST's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate DEST's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if DEST's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if DEST's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of DEST's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.1yrs

Average management tenure


CEO

Neil Clark (58 yo)

4.5yrs

Tenure

UK£325,000

Compensation

Mr. Neil Robert Clark, BSc, FCA, has been the Chief Executive Officer and Executive Director at Destiny Pharma plc since April 13, 2017 and January 20, 2017 respectively. Mr. Clark has been Consultant of P...


CEO Compensation Analysis

Compensation vs Market: Neil's total compensation ($USD447.24K) is above average for companies of similar size in the UK market ($USD330.27K).

Compensation vs Earnings: Neil's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: DEST's management team is considered experienced (3.1 years average tenure).


Board Members

Experienced Board: DEST's board of directors are considered experienced (3.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: DEST insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 36.5%.


Top Shareholders

Company Information

Destiny Pharma plc's employee growth, exchange listings and data sources


Key Information

  • Name: Destiny Pharma plc
  • Ticker: DEST
  • Exchange: AIM
  • Founded: 1996
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£66.746m
  • Shares outstanding: 59.86m
  • Website: https://www.destinypharma.com

Number of Employees


Location

  • Destiny Pharma plc
  • Sussex Innovation Centre
  • Unit 36
  • Brighton
  • East Sussex
  • BN1 9SB
  • United Kingdom

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/10/16 17:48
End of Day Share Price2021/10/15 00:00
Earnings2021/06/30
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.